Impact of early systemic lupus erythematosus on work disability-results from the Finnish nationwide register 2000-2007 by Elfving, Pia et al.
BRIEF REPORT
Impact of early systemic lupus erythematosus on work
disability—results from the Finnish nationwide register 2000–2007
Pia Elfving1 & Kari Puolakka2 & Vappu Rantalaiho3,4 & Hannu Kautiainen5,6,7 & Lauri J. Virta8 &
Oili Kaipiainen-Seppänen1
Received: 14 November 2017 /Revised: 4 February 2018 /Accepted: 6 March 2018 /Published online: 14 March 2018
# International League of Associations for Rheumatology (ILAR) 2018
Abstract
Objectives of this study were to examine work disability (WD) and its leading causes in incident SLE patients. Data were derived
from the Finnish nationwide registries to identify all non-retired, 18 to 64-year-old incident SLE patients between 2000 and 2007.
Sick benefits andWD pensions and the causes for themwere monitored until the end of 2008. A total of 446 working-aged, incident
SLE patients available for work force (mean age 42 ± 13 years, 89% females) were found. During the follow-up (median 5.3 years),
WD pension was granted to 27 patients. The most common cause was SLE itself (14 patients, 52%), with cumulative incidence of
3.4% (95% CI 1.9 to 5.8) in 5 years and 5.0% (95% CI 3.0 to 8.5) in 8 years, followed by musculoskeletal and psychiatric causes.
The age- and sex- adjusted incidence ratio for WD pension in SLE patients due to any cause was 5.4 (95% CI 3.7 to 7.9) compared
to the Finnish population. The mean number of WD days was 32 (95% CI 28 to 35) per patient-year among all SLE patients during
the follow-up. The study concludes that SLE patients have an increased risk for WD already in early course of the disease.
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Introduction
Systemic lupus erythematosus (SLE) often affects working-
aged adults and has an unpredictable nature with multiple
organ manifestations [1]. This may influence on functional
capacity and result diminished work productivity, which in
turn translates in indirect costs. The German cost of illness
study on four rheumatic diseases (SLE, rheumatoid arthritis,
ankylosing spondylitis, and psoriatic arthritis) showed the
highest indirect costs in SLE especially due to sick leaves
and permanent work disability (WD) [2]. Available data on
WD in SLE is limited. Studies are heterogeneous in terms of
patient cohorts, definition of WD, social insurance, and labor
market [2–16].
The aim of the study was to explore the occurrence and
causes of disability pensions and the number of WD days in
incident SLE patients in Finland.
Methods
Finland has amainly Caucasian (> 98%) population. In the year
2008, the working-aged population was 3.4 million people
[17]. The permanent residents are covered by the National
Health Insurance, which provides reimbursement for expenses
caused by illnesses. The Social Insurance Institution (SII)
grants a higher special reimbursement for expenses of drugs
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used in outpatient treatment of certain severe and chronic med-
ical conditions, including SLE. In order to apply for special
reimbursement, a patient has to file a medical certificate, which
is normally drawn up at the time of diagnosis by the doctor
specialized in SLE treatment. If a sickness causes inability to
work, working-aged Finnish citizens are eligible for compen-
sated sickness allowance after ten weekdays waiting period
from the SII. The sickness allowance is paid for up to 300
weekdays. If incapacity to work lasts over 300 days, the indi-
vidual is eligible for disability pension, either temporary or
permanent, full-time or part-time. The data of the sickness ben-
efits and WD pensions are gathered into the registries main-
tained by the SII and the Finnish Centre for Pensions [18].
Working-aged (18–64 years), non-retired incident SLE pa-
tients were identified from special reimbursement register be-
tween January 1st 2000 and December 31st 2007. The date of
reimbursement decision was defined as the onset of SLE (index
day). The patients were linked to the national sickness allowance
and pension registries from the index date until any of the fol-
lowing events: death, age of 65 years, WD pension, normal old-
age pension, or the end of 2008.
The data on WD days comprised of sick leaves over
10 days, temporary, part-time, and permanent WD pensions.
The number of all WD days was calculated per patient-year.
The cumulative incidence of WD pension contained all per-
manent WD pensions after the onset of the disease and those
long-term temporary WD pensions that continued over the
end of follow-up 31.12.2008.
The main causes of theWD pensions were evaluated by the
International Classification of Diseases 10 (ICD-10) codes on
the pension register data. The data on newWD pensions in the
Finnish population were obtained from the same source.
Statistical methods
Descriptive values are expressed as means with standard devia-
tions (SDs) or as medians with interquartile ranges (IQRs).
Cumulative incidence for WD pensions with 95% confidence
intervals (CIs) was estimated and illustrated by the Kaplan-
Meier method. The 95%CIs for annualWD days were obtained
by bias-corrected bootstrapping and the linearity across year
cohorts was tested by bootstrap-type analysis of covariance with
an appropriate contrast. The standardized incidence ratio for a
WD pension in SLE cohort is the ratio between observed and
expected numbers of WD pensions in the age, sex, and calendar
year stratum-specific general population andwas calculatedwith
95% CIs assuming a Poisson distribution.
Results
A total of 446 non-retired 18 to 64-year-old incident SLE
patients were identified. Mean age at diagnosis was 42 ±
13 years for 398 females and 46 ± 12 years for 48 males.
The median (IQR) follow-up time was 5.3 (3.0, 7.0) years.
Twenty-seven (22 females) patients retired on permanent
WD pension during the follow-up. The main cause was SLE
in 14 (52%) patients, followed by musculoskeletal and psy-
chiatric diseases, with five (19%) patients in both categories.
Breast cancer, heart failure, and muscular dystrophy each
caused permanent WD pension in one individual.
The cumulative incidences for all type WD pensions are
shown in Fig. 1. After 5 years 5.8% (95% CI 3.9 to 8.7) and at
the end of follow-up, 8.6% (95%CI 5.6 to 13.1) of the patients
receivedWD pension due to any disease cause. The respective
numbers for SLE-associated WD pensions were 3.4% (95%
CI 1.9 to 5.8) and 5.0% (95%CI 3.0 to 8.5). The age- and sex-
adjusted incidence ratio for WD pension due to any cause was
5.4 (95% CI 3.7 to 7.9) compared to the Finnish population.
Figure 2 shows the annual number of WD days after the
SLE diagnosis. The number increased during the follow-up (P
for linearity = 0.007). A total of 257 (58%) SLE patients had
WD days and the mean number of WD days was 32 (95% CI
28 to 35) days per patient-year among all SLE patients.
Fig. 1 Cumulative incidence for
work disability (WD) pension due
to systemic lupus erythematosus
(SLE) and due to any cause
among 446 working-aged
incident SLE patients after the
diagnosis of SLE. Gray area
shows the 95% confidence
intervals
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Discussion
In this register-based nationwide longitudinal study, the risk of
disability pension was over 5 times higher in incident SLE
patients than in the population. The primary cause behind
the WD was SLE itself. Many SLE patients have difficulties
in maintaining their ability to work already in the early course
of the disease in Finland.
The literature on SLE-induced decreased working ca-
pacity is scattered and limited. The existing data generally
include small numbers of SLE patients and patient iden-
tification differs [3–16, 19]. Any comparison between
countries is impeded by different work-related societal
factors and definitions of WD. Many female patients are
homemakers and their lower functional capacity is not
considered in WD statistics. WD rates in previous SLE
studies range generally between 13 to 43% and disease
durations between 3 to 18 years [3–16]. Our results are
parallel to the previous data.
The WD studies on early SLE are rare [7, 10, 11]. In a
Chinese cross-sectional study, over half of those working-
aged SLE patients who failed to work at 10 years after the
diagnosis were unable to work already in the first 2 years of
disease [10]. AUSmulti-center study detected permanentWD
among 40% of patients after 3.4 years of diagnosis [11]. A
Canadian study on incident SLE reported progressively in-
creasing rate of WD along time being 13% at 2 years, 19%
at 5 years, and 21% at 10 years [7]. In the present study, within
5 years, 6% of SLE patients were retired due to health
grounds, which is a one-third of that in Canada. Strict
pension-based definition of WD and unselected SLE patients
may partly explain the lower rate in the present study.
A multi-center cross-sectional study from the USA com-
pared the work participation of 344 subjects with SLE to 322
controls. Consistently with the earlier reports, SLE patients
had significantly higher rates of WD (31%) compared with
controls (4%) [14]. Likewise, a cross-sectional Finnish study
on female working-aged patients in a hospital-based cohort
showed the rate of permanent WD of 34% in SLE cohort
versus 10% of controls. SLE-related cumulative WD within
5, 10, and 20 years since diagnosis was 13, 22, and 47%,
respectively [8].
In the present study, 58% of SLE patients had > 10 week-
days lasting WD periods (a mean of 32 days). The number of
long-term WD days increased significantly with time since
diagnosis. In a German cross-sectional study, 36% of 1248
SLE patients with mean disease duration of 10.7 years were
on sick leave at least once in the year preceding the study. The
mean annual loss of working time was 9.9 weeks [20].
Consistently, the Carolina Lupus Study on early SLE among
198 patients reported that 21% of SLE patients versus 11% of
controls had sickness absence periods lasting over 14 days in
the past 12 months [6]. In a previous Finnish study, SLE
patients had missed 2.5 times more working days in the past
year than controls [8]. A Dutch study showed also tendency
for long periods of lost work days due to SLE [5].
The identification of SLE-associated WD in our study are
based on reliable official register data in contrast to the most
studies relying on patients self-reports either in interviews or
in questionnaires [4, 8, 10, 16]. Our study has the strengths of
longitudinal study setting, nationwide coverage, and compar-
ison with the general population.
Some limitations should be acknowledged. The present
study misses sick leaves lasting ≤ 10 days and therefore under-
estimates the true number ofWD days. Longer follow-up could
reveal any trends in work participation along time. The study
lacks clinical data and data about fulfillment of diagnostic
criteria. Therefore, the disease-related predictors of WD remain
unknown. However, for the special reimbursement, diagnosis
of SLE was confirmed both by the specialist and the SII. The
present study assesses WD over 9 years since the turn of mil-
lennium. Further studies with updated data are needed.
In conclusion, the incident SLE patients have significantly
higher risk for WD compared to the population. The SLE itself
is the leading cause behind excess WD. These observations
underline the importance of early occupational and drug thera-
py interventions in order to keep SLE patients in working life.
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Fig. 2 Number of work disability (WD) days due to any disease cause per
patient-year after systemic lupus erythematosus (SLE) diagnosis in the
incident SLE cohort
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